文献速递肿瘤 PET/CT

前列腺癌分期迁移:PSMA-PET在识别寡转移性疾病中的作用

Stage migration in prostate cancer: the role of PSMA-PET in identifying oligometastatic disease.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-09-28

本多中心回顾性研究纳入497例中高危前列腺癌患者,比较PSMA-PET与常规影像(增强CT和骨显像)对寡转移性疾病(≤3个转移灶)的检出率。结果显示PSMA-PET检出率11.4%(29/255)显著高于常规影像的6.7%(17/255)(p=0.040),且36.5%的病例治疗意向发生改变。

要点

  • PSMA-PET对寡转移检出率11.4%,显著高于常规影像的6.7%(p=0.040)。
  • PSMA-PET导致36.5%病例治疗意向改变,其中18.5%为重大改变。
  • 常规影像可能低估新发转移性前列腺癌,PSMA-PET引起分期迁移。

核心结论

  • PSMA-PET较常规影像检出更多新发寡转移和多转移患者,导致中高危患者分期迁移。
  • 这些发现反映检出率和重新分类的增加,并与治疗意向计划改变相关。
  • 因缺乏独立参考标准或随访,不能确立诊断准确性的改善。

研究设计与样本

  • 多中心回顾性研究,纳入中高危前列腺癌患者,均在四个月内接受PSMA-PET和常规影像(增强CT和骨显像)。
  • 共收集497例患者数据,其中255例符合主要终点分析的纳入/排除标准,所有患者均纳入次要终点分析。
  • 主要终点为比较PSMA-PET与常规影像对寡转移(定义为≤3个转移灶)的检出率;次要终点为评估PSMA-PET发现引起的治疗改变。

主要发现

  • PSMA-PET检出寡转移的患者比例为11.4%(29/255),显著高于常规影像的6.7%(17/255)(p=0.040)。
  • 回顾性多学科审查中,36.5%(93/255)的病例治疗意向发生改变,其中重大改变占18.5%(如从治愈性治疗转为全身治疗),轻微改变占18.0%。
  • 上述治疗改变反映的是意向治疗计划,而非实际实施的治疗。

关键数值与推荐

  • 寡转移定义为≤3个转移灶。
  • PSMA-PET检出寡转移率11.4%(29/255) vs 常规影像6.7%(17/255),p=0.040。
  • 治疗意向改变率36.5%(93/255),重大改变18.5%,轻微改变18.0%。

临床怎么用

  • 在中高危前列腺癌分期中,PSMA-PET可检出更多常规影像遗漏的寡转移和多转移病灶。
  • PSMA-PET结果可能改变治疗意向,如从治愈性治疗转为全身治疗,需结合多学科讨论。
  • 因缺乏随访证据,PSMA-PET对生存的影响尚未确立,临床决策需谨慎权衡。

局限性

  • 回顾性设计。
  • 缺乏中心影像审查。
  • 缺乏患者随访。
  • PSMA-PET对生存的影响尚未确立。
  • 无独立参考标准,不能确立诊断准确性的改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Oligometastatic disease (OMD) represents an intermediate disease state between localized and metastatic prostate cancer (PCa), where patients may still benefit from curative treatments. The prevalence of "de novo" metastatic disease detected by positron emission tomography (PET) with prostate specific membrane antigen (PSMA) in a real-world setting is still to be clarified. The primary aim was to compare the detection rates of OMD between PSMA-PET and conventional imaging (CI) in patients with intermediate- to high-risk PCa. METHODS: This multicenter retrospective study included patients with intermediate- to high-risk PCa who underwent both PSMA-PET and CI (contrast-enhanced CT and bone scintigraphy) within four months. The primary endpoint was to compare the detection rates of OMD (defined as ≤ 3 metastatic) between PSMA-PET and CI. The secondary endpoint was to assess treatment changes prompted by PSMA-PET findings. RESULTS: Data of 497 patients were collected, and 255 patients met inclusion/exclusion criteria for the primary endpoint analysis, and all were considered for the secondary endpoint. OMD was identified using PSMA-PET in 11.4% of patients (29/255), significantly higher than the 6.7% rate (17/255) with CI (p = 0.040). In a retrospective multidisciplinary review, the intended clinical management changed in 36.5% (93/255) of cases, with major changes in 18.5% (e.g. a switch from curative therapy to systemic treatment) and minor changes in 18.0%. This reflects the intended treatment plan, not the treatment delivered. Limitations include the retrospective design, lack of central imaging review and absent patient follow-up. Also, the impact of PSMA-PET on survival has not been established. CONCLUSIONS: This study shows that CI may underestimate de novo metastatic prostate cancer. Compared with CI, PSMA-PET detected more patients with de novo oligometastatic and multimetastatic disease and produced stage migration in intermediate- to high-risk patients. These findings reflect increased detection and reclassification, and were associated with changes in the intended treatment plan. However, because no independent reference standard or follow-up was available, they do not establish improved diagnostic accuracy.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Mattana F, Luzzago S, Dragonetti V, et al. Stage migration in prostate cancer: the role of PSMA-PET in identifying oligometastatic disease. Eur J Nucl Med Mol Imaging. 2026. PMID: 42802268. doi:10.1007/s00259-026-08166-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。